FibromyalgiaPhase 3NCT00883740
Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia
A Phase 3 study testing Pregabalin in people with Fibromyalgia and Sleep Disorders, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 50 sites in 3 countries.
Trial summary
The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fibromyalgia, Sleep Disorders
- What is being tested?
- Pregabalin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 119 participants
- Where
- 50 sitesin 3 countries
- Study dates
- Jun 2009to Jun 2010
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must meet diagnostic criteria for fibromyalgia;
- Subjects must report difficulty in maintaining sleep at least 3 times per week and meet Research Diagnostic Criteria (RDC) for insomnia disorder, corroborated by subject diary, and meet PSG inclusion criteria at visit 3.
Who cannot join
- History of active sleep disorder other than Research Diagnostic Criteria(RDC) insomnia criteria or any sleep or circadian rhythm disturbance;
- Use of medications known to affect sleep wake function by Visit 2;
- Involved in night or rotating shift work, or travel across >4 time zones 14 days prior to screening and during study; regular daytime napping
- PSG finding of apnea/hypopnea or periodic limb movement with arousal index >10/hr on either night of PSG.
Trial locations and contacts
50 sites in 3 countries.
50 sites in 3 countries
United States30 sites
Pfizer Investigational Site
Atlanta, Georgia, 30342
Pfizer Investigational Site
Baton Rouge, Louisiana, 70809
Pfizer Investigational Site
Beachwood, Ohio, 44122
Pfizer Investigational Site
Chicago, Illinois, 60634
Pfizer Investigational Site
Cleveland, Ohio, 44122
Pfizer Investigational Site
Colorado Springs, Colorado, 80909
Pfizer Investigational Site
Columbia, South Carolina, 29201
Pfizer Investigational Site
Crestview Hills, Kentucky, 41017
Pfizer Investigational Site
Dallas, Texas, 75230
Pfizer Investigational Site
Dallas, Texas, 75248
Pfizer Investigational Site
DeLand, Florida, 32720
Pfizer Investigational Site
Duncansville, Pennsylvania, 16635
Pfizer Investigational Site
Hallandale, Florida, 33009
Pfizer Investigational Site
Hattiesburg, Mississippi, 39401
Pfizer Investigational Site
Hattiesburg, Mississippi, 39402
Pfizer Investigational Site
Houston, Texas, 77063
Pfizer Investigational Site
Louisville, Kentucky, 40217
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73103
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Orange City, Florida, 32763
Pfizer Investigational Site
Overland Park, Kansas, 66212
Pfizer Investigational Site
Pembroke Pines, Florida, 33026
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19114
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19139
Pfizer Investigational Site
Phoenix, Arizona, 85013
Pfizer Investigational Site
Phoenix, Arizona, 85020
Pfizer Investigational Site
Raleigh, North Carolina, 27612
Pfizer Investigational Site
San Diego, California, 92102
Pfizer Investigational Site
South Miami, Florida, 33143
Pfizer Investigational Site
Tucson, Arizona, 85741
Canada10 sites
Pfizer Investigational Site
Calgary, Alberta, T2X 3V4
Pfizer Investigational Site
Edmonton, Alberta, T5R 5W5
Pfizer Investigational Site
Kelowna, British Columbia, V1Y 3G8
Pfizer Investigational Site
Kelowna, British Columbia, V1Y 4R9
Pfizer Investigational Site
Mississauga, Ontario, L5B 4M4
Pfizer Investigational Site
Point Edward, Ontario, N7V 1X4
Pfizer Investigational Site
Thornhill, Ontario, L4J 6X2
Pfizer Investigational Site
Toronto, Ontario, M3H 3V6
Pfizer Investigational Site
Toronto, Ontario, M4P 1P2
Pfizer Investigational Site
Toronto, Ontario, M6J 3S3
Germany10 sites
Pfizer Investigational Site
Berlin, 10117
Pfizer Investigational Site
Berlin, 10969
Pfizer Investigational Site
Berlin, 12683
Pfizer Investigational Site
Berlin, 13125
Pfizer Investigational Site
Chemnitz, 09111
Pfizer Investigational Site
Göppingen, 73033
Pfizer Investigational Site
Göppingen, 73035
Pfizer Investigational Site
München, 80336
Pfizer Investigational Site
München, 81675
Pfizer Investigational Site
Schwerin, 19053
About this study
Official title: Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study
The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)
- Conditions
- Fibromyalgia, Sleep Disorders
- Being tested
- Pregabalin, Placebo
- Keywords
- Fibromyalgia sleep maintenance disturbance pregabalin
- Medical subject headings
- Fibromyalgia, Sleep Wake Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PregabalinDrug
Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
PlaceboDrug
Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| Lyrica | Experimental | flexible dosing Lyrica 300-450mg/day Receives: Drug: Pregabalin |
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wake After Sleep Onset (WASO) at Weeks 5 and 11
WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography [PSG]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording [i.e. awake epoch immediately prior to the end of the recording]) on 2 consecutive nights divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)
Secondary outcomes (17)
Wake Time During Sleep (WTDS)
WTDS, as determined by PSG, was the total amount of time awake the participant experienced after the onset of persistent sleep and prior to the final awakening, or at the end of 8 hours of recording. WTDS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Wake Time After Sleep (WTAS)
WTAS, as determined by PSG, was the total amount of time awake after the final awakening until the end of the 8 hours. WTAS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Total Sleep Time (TST)
TST, as determined by PSG, was the number of non-wake epochs from the beginning of recording to the end of the recording. TST was the sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Sleep Efficiency (SE)
SE, as determined by PSG, was the TST divided by the time in bed, multiplied by 100. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Number of Awakenings After Sleep Onset (NAASO 1)
NAASO 1, as determined by PSG, was the number of times there was a wake period of at least one epoch in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage rapid eye movement (REM) epoch. The sum of 2 consecutive nights of recording was divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Number of Awakenings After Sleep Onset (NAASO 2)
NAASO 2, as determined by PSG, was the number of times that there was a wake period of at least two epochs in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage REM epoch. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Latency to Persistent Sleep (LPS)
LPS, as determined by PSG, was the total number of epochs recorded on 2 consecutive nights divided by 2 at the end of each intervention period, from the beginning of the recording to the start of the first 20 consecutive non-wake epochs.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
WASO by Hour of the Night
WASO, as determined by PSG, was the wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual hour (8 hours total).
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
WASO by Each Quarter of the Night
WASO, as determined by PSG, was the sum of wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual quarter of the night (eight hours in 2 hour increments).
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Slow Wave Sleep (SWS)
SWS, as determined by PSG, Stage 3 plus 4 sleep divided by TST times 100 was the percentage of TST. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period.
Measured: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Change From Baseline in MOS-SS Sleep Disturbance at Weeks 5 and 11
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was comprised of 12 items yielding 7 subscale scores and 2 index composite index scores. Sleep Disturbance subscale score (4 items): individual scores were transformed (actual raw score minus lowest possible score divided by possible raw score range times 100) and ranged from 0 to 100; higher score indicated greater disturbance. Total score ranged=0 to 100; higher score indicates greater intensity of attribute. Change was score at week x minus score at baseline.
Measured: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Change From Baseline in MOS-SS Sleep Problems Index II Weeks 5 and 11
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was compromised of 12 items yielding 7 subscale scores and 2 index composite index scores. Composite index included Sleep Problems Index II (9 items), scores ranged from 0 to 100; higher scores indicated greater sleep problems. Change was score at week x minus score at baseline.
Measured: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Sleep Quality
Sleep Quality as meassured by numeric rating scale (NRS), a participant rated scale 0 to 10, (0 = very poor sleep, 10 = excellent sleep). Weekly values were calculated as the average of the participants daily diary scores.
Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Latency of Sleep Onset (LSO)
LSO as reported on daily Subjective Sleep Questionnaire (SSQ), a participant reported subjective estimate of the amount of time to fall asleep after lights out. Weekly values were calculated as the average minutes reported on the participant's daily SSQ.
Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Daily Pain Score
Pain intensity as measured by NRS; a participant rated scale 0 to 10 (0 = no pain to 10 = worst pain possible). Weekly values were calculated as the average of the participants daily pain scores.
Measured: Daily up to Day 73 or ET
Subjective Wake After Sleep Onset (sWASO)
sWASO as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening. Weekly values were calculated as the average of the participant's daily SSQ values.
Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Subjective Total Sleep Time (sTST)
sTST as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was asleep after lights out until final awakening. Weekly values were calculated as the average of the participants daily SSQ values.
Measured: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2009 (estimated)
- Study startJun 2009
- Primary completionJun 2010
- Study completionJun 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 119 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00883740
- Sponsor's protocol ID
- A0081165
- Status last verified
- Jul 2011
- First submitted
- 17 Apr 2009
- Last updated
- 25 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken). 2012 Apr;64(4):597-606. doi: 10.1002/acr.21595.
PubMed 22232085
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study
- ClinicalTrials.gov ID
- NCT00883740
- Acronym / sponsor ID
- A0081165
- Conditions
- Fibromyalgia, Sleep Disorders
- Keywords
- Fibromyalgia sleep maintenance disturbance pregabalin
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 119 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Jun 2009
- Primary completion
- Jun 2010 (actual)
- Study completion
- Jun 2010 (actual)
- First posted
- 20 Apr 2009 (estimated)
- Results
- Posted 10 Aug 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lyrica | Experimental | Drug: Pregabalinflexible dosing Lyrica 300-450mg/day |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Subjects must meet diagnostic criteria for fibromyalgia;
- Subjects must report difficulty in maintaining sleep at least 3 times per week and meet Research Diagnostic Criteria (RDC) for insomnia disorder, corroborated by subject diary, and meet PSG inclusion criteria at visit 3.
Key exclusion criteria (4 listed)
- History of active sleep disorder other than Research Diagnostic Criteria(RDC) insomnia criteria or any sleep or circadian rhythm disturbance;
- Use of medications known to affect sleep wake function by Visit 2;
- Involved in night or rotating shift work, or travel across >4 time zones 14 days prior to screening and during study; regular daytime napping
- PSG finding of apnea/hypopnea or periodic limb movement with arousal index >10/hr on either night of PSG.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PregabalinCapsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day | Drug | Lyrica |
| PlaceboCapsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks | Drug | Placebo |
Primary outcome
Wake After Sleep Onset (WASO) at Weeks 5 and 11
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)
WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography [PSG]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording [i.e. awake epoch immediately prior to the end of the recording]) on 2 consecutive nights divided by 2 at the end of each intervention period.
17 secondary outcomes
Wake Time During Sleep (WTDS)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Wake Time After Sleep (WTAS)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Total Sleep Time (TST)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Sleep Efficiency (SE)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Number of Awakenings After Sleep Onset (NAASO 1)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Number of Awakenings After Sleep Onset (NAASO 2)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Latency to Persistent Sleep (LPS)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
WASO by Hour of the Night
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
WASO by Each Quarter of the Night
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Slow Wave Sleep (SWS)
Time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Change From Baseline in MOS-SS Sleep Disturbance at Weeks 5 and 11
Time frame: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Change From Baseline in MOS-SS Sleep Problems Index II Weeks 5 and 11
Time frame: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Sleep Quality
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Latency of Sleep Onset (LSO)
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Daily Pain Score
Time frame: Daily up to Day 73 or ET
Subjective Wake After Sleep Onset (sWASO)
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Subjective Total Sleep Time (sTST)
Time frame: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 22232085Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken). 2012 Apr;64(4):597-606. doi: 10.1002/acr.21595.
Related trials for Fibromyalgia
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Recruiting
Auricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia
Fibromyalgia Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
50 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pregabalin in people with Fibromyalgia and Sleep Disorders, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 50 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 50 sites in United States, Canada, Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Aug 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wake After Sleep Onset (WASO) at Weeks 5 and 11 (time frame: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00883740, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.